Reply to Letter to the Editor: "Critical Appraisal of Isorhamnetin as a Candidate for Pulmonary Arterial Hypertension Treatment".
作者信息
Liu Yang
机构信息
Department of Internal and Pediatrics, School of Clinical Medicine, Qilu Medical University, Zibo, Shandong, China.
出版信息
Anatol J Cardiol. 2025 May 2;29(7):376. doi: 10.14744/AnatolJCardiol.2025.5304.
Abstract
摘要
相似文献
1
Reply to Letter to the Editor: "Critical Appraisal of Isorhamnetin as a Candidate for Pulmonary Arterial Hypertension Treatment".致编辑信的回复：“对异鼠李素作为肺动脉高压治疗候选药物的批判性评价”
Anatol J Cardiol. 2025 May 2;29(7):376. doi: 10.14744/AnatolJCardiol.2025.5304.
2
Critical Appraisal of Isorhamnetin as a Candidate for Pulmonary Arterial Hypertension Treatment.异鼠李素作为肺动脉高压治疗候选药物的批判性评价
Anatol J Cardiol. 2025 May 7;29(7):375. doi: 10.14744/AnatolJCardiol.2025.5303.
3
Evidence synthesis in pulmonary arterial hypertension: a systematic review and critical appraisal.肺动脉高压的证据综合：系统评价与批判性评价。
BMC Pulm Med. 2020 Jul 28;20(1):202. doi: 10.1186/s12890-020-01241-4.
4
Clinical guidelines and payer policies on fusion for the treatment of chronic low back pain.临床指南和支付方政策对慢性下腰痛融合治疗的影响。
Spine (Phila Pa 1976). 2011 Oct 1;36(21 Suppl):S144-63. doi: 10.1097/BRS.0b013e31822ef5b4.
5
Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants.布洛芬用于治疗早产和/或低出生体重婴儿的动脉导管未闭。
Cochrane Database Syst Rev. 2008 Jan 23(1):CD003481. doi: 10.1002/14651858.CD003481.pub3.
6
OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence.骨关节炎研究学会国际联盟（OARSI）关于髋和膝骨关节炎管理的建议，第一部分：对现有治疗指南的批判性评估及当前研究证据的系统评价
Osteoarthritis Cartilage. 2007 Sep;15(9):981-1000. doi: 10.1016/j.joca.2007.06.014. Epub 2007 Aug 27.
7
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.氯吡格雷和双嘧达莫缓释制剂预防闭塞性血管事件（技术评估 90 号回顾）：系统评价和经济分析。
Health Technol Assess. 2011 Sep;15(31):1-178. doi: 10.3310/hta15310.
8
Guanylate cyclase stimulators for pulmonary hypertension.用于肺动脉高压的鸟苷酸环化酶刺激剂。
Cochrane Database Syst Rev. 2016 Aug 2;2016(8):CD011205. doi: 10.1002/14651858.CD011205.pub2.
9
Endothelin receptor antagonists for pulmonary arterial hypertension.用于治疗肺动脉高压的内皮素受体拮抗剂。
Cochrane Database Syst Rev. 2006 Jul 19(3):CD004434. doi: 10.1002/14651858.CD004434.pub3.
10
Immunosuppression for the treatment of pulmonary hypertension in patients with systemic lupus erythematosus: A systematic review.系统性红斑狼疮相关肺动脉高压的免疫抑制治疗：系统评价。
Int J Rheum Dis. 2023 Jun;26(6):1022-1028. doi: 10.1111/1756-185X.14706. Epub 2023 May 4.
本文引用的文献
1
Critical Appraisal of Isorhamnetin as a Candidate for Pulmonary Arterial Hypertension Treatment.异鼠李素作为肺动脉高压治疗候选药物的批判性评价
Anatol J Cardiol. 2025 May 7;29(7):375. doi: 10.14744/AnatolJCardiol.2025.5303.
2
Bioinformatic Analysis and Molecular Docking Identify Isorhamnetin Is a Candidate Compound in the Treatment of Pulmonary Artery Hypertension.生物信息学分析和分子对接表明异鼠李素是治疗肺动脉高压的候选化合物。
Anatol J Cardiol. 2025 Nov 28;29(2):52-65. doi: 10.14744/AnatolJCardiol.2024.4723.
Zotero 插件